Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06029972 · ClinicalTrials.gov registry record · Phase 2

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2 study of Ulcerative Colitis, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 2
Development phase
176
Enrollment target
20
Study locations

NCT06029972 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 176 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06029972, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 2
Development phase
176 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.

Conditions Studied

Ulcerative Colitis

Interventions

  • DRUG Placebo
  • DRUG Tilpisertib Fosmecarbil

Study Locations (20)

California

  • GastroSb Weight Loss Clinic - Chula Vista
  • Southern California Research Centers - Coronado
  • VVCRD Research - Garden Grove
  • UC San Diego Health System - La Jolla
  • Gastro Care Institute - Lancaster
  • Om Research LLC - Lancaster
  • United Medical Doctors - Murrieta
  • University of California, Davis - Sacramento
  • University of California San Francisco - San Francisco
  • Amicis Research Center - Valencia

Florida

  • Luna Research - Coral Gables
  • University of Florida - Gainesville
  • The Medici Medical Research - Hollywood
  • Encore Medical Research, LLC - Hollywood
  • Clinical Research of Osceola - Kissimmee
  • Florida Research Institute - Largo
  • Wellness Research Center - Miami
  • IMIC Inc - Miami
  • Reserka LLC - Miami

Arizona

  • GI Alliance - Sun City

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2023-12-05
Est. Completion 2028-02
Phase Phase 2

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06029972

The ClinicalTrials.gov registry entry for NCT06029972 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (91% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06029972 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06029972 about?

NCT06029972 is a clinical study titled "Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis". The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participant...

What is the current status of trial NCT06029972?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2023-12-05. Estimated completion is 2028-02.

What conditions does trial NCT06029972 study?

This clinical trial studies the following conditions: Ulcerative Colitis.

What interventions are being tested in trial NCT06029972?

The interventions under investigation include: Placebo (DRUG), Tilpisertib Fosmecarbil (DRUG).

Who is sponsoring clinical trial NCT06029972?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06029972 being conducted?

This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.